BIOCON391.00

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹63,381 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity4.053.661.051.05
Return on Assets2.312.430.580.58
Return on Capital Employed4.253.333.023.02
Return on Invested Capital3.762.682.552.68
Margins
EBITDA Margin22.3620.7520.4120.42
Operating Margin11.729.698.858.85
Incremental Operating Margin-49.531.16
Pretax Margin10.9112.362.652.76
Net Income Margin8.809.372.182.40
Net Income to Common Margin6.936.642.282.86
FCF Margin6.9311.260.490.49
Additional
Effective Tax Rate14.1324.2317.6613.00
Dvd Payout Ratio15.645.8024.62
Sustainable Growth Rate3.423.450.791.05
Incremental Operating Margin %-49.531.16-2.87
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.